FDA Approves PRIMAQUINE PHOSPHATE — Ingenus Pharmaceuticals, LLC

Ingenus Pharmaceuticals announced today that it received FDA approval for the ANDA206043, granting market exclusivity to its generic version of Primaquine Phosphate. This approval introduces a cost-effective alternative to the brand-name therapy, expected to capture market share as healthcare providers and payers seek managed care solutions.